Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001558370-20-004661
Filing Date
2020-04-29
Accepted
2020-04-29 16:40:57
Documents
7
Effectiveness Date
2020-04-29

Document Format Files

Seq Description Document Type Size
1 DEFA14A tmb-20200429xdefa14a.htm DEFA14A 63365
2 GRAPHIC tmb-20200429xdefa14ag001.jpg GRAPHIC 4955
3 GRAPHIC tmb-20200429xdefa14ag002.jpg GRAPHIC 842
4 GRAPHIC tmb-20200429xdefa14ag003.jpg GRAPHIC 825
5 GRAPHIC tmb-20200429xdefa14ag004.jpg GRAPHIC 1657
6 GRAPHIC tmb-20200429xdefa14ag005.jpg GRAPHIC 1505
7 GRAPHIC tmb-20200429xdefa14ag006.jpg GRAPHIC 915
  Complete submission text file 0001558370-20-004661.txt   80075
Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39069 | Film No.: 20830993
SIC: 2834 Pharmaceutical Preparations